These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28875477)

  • 21. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
    Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
    Zhuo X; Zhuo B; Ouyang S; Niu P; Xiao M
    BMC Pharmacol Toxicol; 2018 Sep; 19(1):54. PubMed ID: 30176938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
    Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.
    Trenk D; Hochholzer W; Fromm MF; Zolk O; Valina CM; Stratz C; Neumann FJ
    Circ Cardiovasc Genet; 2011 Aug; 4(4):429-36. PubMed ID: 21685174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
    BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
    Verlinden NJ; Coons JC; Iasella CJ; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2017 Nov; 22(6):546-551. PubMed ID: 28279076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: A systematic review and meta-analysis.
    Fortuni F; Ferlini M; Leonardi S; Angelini F; Crimi G; Somaschini A; Cornara S; Potenza A; De Servi S; Oltrona Visconti L; De Ferrari GM
    Int J Cardiol; 2018 Dec; 273():80-87. PubMed ID: 30115419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients).
    Baber U; Li SX; Pinnelas R; Pocock SJ; Krucoff MW; Ariti C; Gibson CM; Steg PG; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Iakovou I; Dangas G; Aquino MB; Sartori S; Chieffo A; Moliterno DJ; Colombo A; Mehran R
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e006144. PubMed ID: 29870385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PXR polymorphisms have impact on the clinical efficacy of clopidogrel in patients undergoing percutaneous coronary intervention.
    Wu Y; Yu H; Tang HQ; Su Y; Shi TL; Liu S; Xia Q; Xu DJ
    Gene; 2018 May; 653():22-28. PubMed ID: 29432831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
    Gajos G; Rostoff P; Undas A; Piwowarska W
    J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
    Novkovic M; Matic D; Kusic-Tisma J; Antonijevic N; Radojkovic D; Rakicevic L
    Eur J Clin Pharmacol; 2018 Apr; 74(4):443-451. PubMed ID: 29260275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for a cluster randomized controlled trial.
    Li J; Ju J; Chen Z; Liu J; Lu F; Gao R; Xu H
    Trials; 2018 Feb; 19(1):93. PubMed ID: 29415754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
    JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
    Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M
    JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy.
    Tang QJ; Lei HP; Wu H; Chen JY; Deng CY; Sheng WS; Fu YH; Li XH; Lin YB; Han YL; Zhong SL
    Acta Pharmacol Sin; 2019 Feb; 40(2):208-215. PubMed ID: 29891858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Aronow HD; Steinhubl SR; Brennan DM; Berger PB; Topol EJ;
    Am Heart J; 2009 Feb; 157(2):369-74. PubMed ID: 19185647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
    Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
    Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.